{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:13:28Z","timestamp":1787022808499,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:p>\n                    Managing the symptoms of menopause after a diagnosis of breast cancer offers some unique clinical challenges. For some women, vasomotor symptoms can be severe and debilitating, and hormone therapy is at least relatively contraindicated. Non-oestrogen therapies for hot flushes include SSRIs, clonidine, gabapentin and perhaps black cohosh extracts. Vulvovaginal atrophy can usually be alleviated by simple moisturizers, although some may need specialized physiotherapy such as vaginal dilators. In a small number, topical oestrogens may be the only treatment that works. The CO\n                    <jats:sub>2<\/jats:sub>\n                    laser may be a novel, non-oestrogen therapy to alleviate this unpleasant symptom. Bone loss can be accelerated in some patients on AIs or those who had early menopause induced by chemotherapy.\n                  <\/jats:p>","DOI":"10.1530\/eje-15-0814","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T23:27:58Z","timestamp":1444865278000},"page":"R71-R77","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":15,"title":["ENDOCRINE DILEMMA: Managing menopausal symptoms after breast cancer"],"prefix":"10.1093","volume":"174","author":[{"given":"John","family":"Eden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2016011518231041000_174.3.R71.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70316-8"},{"key":"2016011518231041000_174.3.R71.2","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00432-013-1491-4","article-title":"The efficacy of nonestrogenic therapy to hot flushes in cancer patients under hormonal manipulation therapy: a systematic review and meta-analysis","volume":"139","author":"Yamaguchi","year":"2013","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"2016011518231041000_174.3.R71.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2057"},{"key":"2016011518231041000_174.3.R71.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2007.09.017"},{"key":"2016011518231041000_174.3.R71.5","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0298"},{"key":"2016011518231041000_174.3.R71.6","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000248705.07333.27"},{"key":"2016011518231041000_174.3.R71.7","doi-asserted-by":"publisher","DOI":"10.2165\/0002512-200926010-00002"},{"key":"2016011518231041000_174.3.R71.8","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000196504.49378.83"},{"key":"2016011518231041000_174.3.R71.9","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000158865.98070.89"},{"key":"2016011518231041000_174.3.R71.10","doi-asserted-by":"publisher","DOI":"10.1080\/09513590400020922"},{"key":"2016011518231041000_174.3.R71.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2004.10.003"},{"key":"2016011518231041000_174.3.R71.12","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181c5159c"},{"key":"2016011518231041000_174.3.R71.13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11606-013-2535-9","article-title":"SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials","volume":"29","author":"Shams","year":"2013","journal-title":"Journal of General Internal Medicine"},{"key":"2016011518231041000_174.3.R71.14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg108"},{"key":"2016011518231041000_174.3.R71.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.4.395"},{"key":"2016011518231041000_174.3.R71.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0138-7"},{"key":"2016011518231041000_174.3.R71.17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl478"},{"key":"2016011518231041000_174.3.R71.18","first-page":"3962","article-title":"Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Boekhout","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"2016011518231041000_174.3.R71.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.02.006"},{"key":"2016011518231041000_174.3.R71.20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/IJGM.S45880","article-title":"Potential role of gabapentin and extended-release gabapentin in the management of menopausal hot flashes","volume":"6","author":"Yadav","year":"2013","journal-title":"International Journal of General Medicine"},{"key":"2016011518231041000_174.3.R71.21","doi-asserted-by":"publisher","DOI":"10.1007\/BF01811960"},{"key":"2016011518231041000_174.3.R71.22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf151"},{"key":"2016011518231041000_174.3.R71.23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5694\/j.1326-5377.2002.tb04835.x","article-title":"Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality","volume":"177","author":"Durna","year":"2002","journal-title":"Medical Journal of Australia"},{"key":"2016011518231041000_174.3.R71.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"2016011518231041000_174.3.R71.25","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018774302092"},{"key":"2016011518231041000_174.3.R71.26","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.201"},{"key":"2016011518231041000_174.3.R71.27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomized trial","volume":"49","author":"Fahlen","year":"2013","journal-title":"European Journal of Cancer"},{"key":"2016011518231041000_174.3.R71.28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn058"},{"key":"2016011518231041000_174.3.R71.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70341-3"},{"key":"2016011518231041000_174.3.R71.30","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2012.756466"},{"key":"2016011518231041000_174.3.R71.31","doi-asserted-by":"publisher","DOI":"10.1080\/713605341"},{"key":"2016011518231041000_174.3.R71.32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2014.975197","article-title":"Sexual function after fractional microablative CO2 lser in women with vulvovaginal atrophy","volume":"18","author":"Salvatore","year":"2015","journal-title":"Climacteric"},{"key":"2016011518231041000_174.3.R71.33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2013.03.034","article-title":"Denosumab in breast cancer treatment","volume":"717","author":"Drooger","year":"2013","journal-title":"European Journal of Pharmacology"},{"key":"2016011518231041000_174.3.R71.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"2016011518231041000_174.3.R71.35","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/01.med.0000436195.10599.dd","article-title":"Breast Cancer and Osteoporosis","volume":"20","author":"Cheung","year":"2013","journal-title":"Current Opinion in Endocrinology, Diabetes and Obesity"},{"key":"2016011518231041000_174.3.R71.36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1586\/17446651.2013.811892","article-title":"Saving the bones in breast cancer: aromatase inhibitor-induced osteoporosis","volume":"8","author":"Agrawal","year":"2013","journal-title":"Expert Review of Endocrinology & Metabolism"},{"key":"2016011518231041000_174.3.R71.37","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00198-013-2615-z","article-title":"Effects of zoledronic acid on bone density in premenopausal women receiving neoadjuvant or adjuvant therapies of HR+ breast cancer: the ProBONE II study","volume":"25","author":"Hadji","year":"2014","journal-title":"Osteoporosis International"},{"key":"2016011518231041000_174.3.R71.38","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00198-015-3100-7","article-title":"Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled trial","volume":"26","author":"Greenspan","year":"2015","journal-title":"Osteoporosis International"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/3\/R71.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/3\/R71.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:33:16Z","timestamp":1676374396000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/174\/3\/R71\/6655510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":38,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1530\/eje-15-0814","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}